摘要
Gut microbiota is a community of microorganisms that reside in the gastrointestinaltract. An increasing number of studies has demonstrated that the gutliveraxis plays a critical role in liver homeostasis. Dysbiosis of gut microbiota cancause liver diseases, including nonalcoholic fatty liver disease and alcoholic liverdisease. Preclinical and clinical investigations have substantiated that themetabolites and other molecules derived from gut microbiota and diet interactionfunction as mediators to cause liver fibrosis, cirrhosis, and final cancer. This effecthas been demonstrated to be associated with dysregulation of intrahepaticimmunity and liver metabolism. Targeting these findings have led to thedevelopment of novel preventive and therapeutic strategies. Here, we review thecellular and molecular mechanisms underlying gut microbiota-mediated impacton liver disease. We also summarize the advancement of gut microbiota-basedtherapeutic strategies in the control of liver diseases.
基金
NIH Grant,No.R01CA208396
and VA Merit Award,No.I01 BX004065-1.